HENLIUS (02696): New Indications for HANSIZHUANG and Futanning Included in the National Reimbursement Drug List

date
18:35 15/11/2026
avatar
GMT Eight
HENLIUS (02696) announced that recently, HANSIZHUANG (serplulimab injection) was included in the Class B scope of the "National Drug Catalog for Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance (2026)" for the first time, and the included indications cover all indications approved for marketing in China (excluding Hong Kong, Macao, and Taiwan, the same below). In addition, Futanning (voruciclib citrate capsules) had its second indication newly included in the National Reimbursement Drug List. The new version of the National Reimbursement Drug List will officially take effect on January 1, 2027.
HENLIUS (02696) announced that recently, HANSIZHUANG (serplulimab injection) was included in the Class B scope of the "National Drug Catalog for Basic Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance (2026)" for the first time, with the included indications covering all indications approved for marketing in China (excluding Hong Kong, Macao, and Taiwan, the same below). In addition, Futanning (voruciclib citrate capsules) had its second indication newly included in the National Reimbursement Drug List. The new version of the National Reimbursement Drug List will be officially implemented starting January 1, 2027. The inclusion of the new indications of HANSIZHUANG and Futanning in the National Reimbursement Drug List this time reflects the National Healthcare Security Administration's recognition of these products in terms of clinical value, patient benefits, and degree of innovation, enhances drug accessibility, reduces patients' medication burden, and is also conducive to promoting the market promotion and sales layout of these products.